Piramal Enterprises Ltd. (PEL), the diversified Indian healthcare to financial services group and active M&A participant, plans to deploy a “blended” strategy to expand its critical care business, including in-licensing products in the near-to-medium term.
Peter DeYoung CEO of Piramal Critical Care outlined four key prongs of the company’s growth strategy, including building on the core inhalation anesthetics business, steering the upcoming launch and commercialization of desflurane in the US successfully, and transitioning and integrating the recent
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?